Artiva Biotherapeutics, Inc. Common Stock

ARTVNASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
9.76 USD
↗ 0.72 (7.96%)AT CLOSE (11:59 AM EDT)
10.16
↗ 0.40 (4.12%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
10.16
↗ 0.40 (4.12%)
🔴Market: CLOSED

ARTV is currently priced at $9.76. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, ARTV trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jul 17, 2026.

Open?$8.89
High?$10.12
Low?$8.75
Prev. Close?$9.04
Volume?360.2K
Avg. Volume?634.7K
VWAP?$9.65
Rel. Volume?0.57x
Bid / Ask
Bid?$9.85 × 500
Ask?$10.65 × 5.0K
Spread?$0.80
Midpoint?$10.25
Valuation & Ratios
Market Cap?474.2M
Shares Out?24.7M
Float?5.7M
Float %?23.2%
P/E Ratio?N/A
P/B Ratio?5.40
EPS?-$1.79
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerBiotech - Drug Development›Clinical-Stage Platforms
Employees
106
Market Cap
439.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.artivabio.com
Listed
2024-07-19
Address
5505 MOREHOUSE DRIVE
SAN DIEGO, CA 92121
Phone: (858) 267-4467
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
28
Piotroski F-Score?0/9Weak
Altman Z-Score?9.05Safe
Confidence?41%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?23.55%Squeeze Risk
Short Interest?1.3M
Days to Cover?1.8
Free Float5.7M
Avg Daily Volume734.6K
Settlement Date2026-06-30
Financial Health
Current Ratio?8.16Strong
Quick Ratio?8.16Strong
Cash Ratio?1.93Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
34
5.40FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.1CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-99.1%WEAK▾
ROA?
S&P
3
-82.2%WEAK▾
Cash Flow & Enterprise
FCF?$-80178000
Enterprise Value?$453.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist